<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The most important goal in the treatment of patients with <z:mp ids='MP_0002055'>diabetes</z:mp> is to lower the risk of long-term <z:mp ids='MP_0002055'>diabetes</z:mp> complications </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">Hyperglycaemia</z:e> is the most important risk factor for microvascular complications in <z:mp ids='MP_0002055'>diabetes</z:mp>, but, in addition to <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, several other risk factors, particularly <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e>, elevated blood pressure and smoking, also determine the risk of macrovascular complications </plain></SENT>
<SENT sid="2" pm="."><plain>In this review, we present evidence from longitudinal population-based studies that <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> is an important risk factor for long-term complications of <z:mp ids='MP_0002055'>diabetes</z:mp> and discuss the results from clinical trials of the effects of the treatment of <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> on the prevention of long-term micro- and macrovascular complications in type 1 and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>An HbA(1c) target of &lt;7.0% for the treatment of <z:mp ids='MP_0002055'>diabetes</z:mp> is generally accepted on the basis of evidence from several trials, whereas a target of &lt;6.5% may be reasonable for patients with a short duration of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and without extensive <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
</text></document>